Benzinga | Sep 17, 2020 07:12AM EDT

ALX Oncology Added To Russell 2000 And 3000 Indexes

BURLINGAME, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it will be added as a member of the Russell 2000(r) and 3000(r) Indexes, effective after the U.S. market opens tomorrow, September 18, 2020, as a part of Russell's quarterly additions of select initial public offering ("IPO") companies.